Menene madauki na gano peptide na asali na AI a haƙiƙa yana buƙatar a gefen gwaji?
Rufaffen madauki yana amfani da sakamakon gwaji don sanar da shawarwarin ƙira na gaba. Yana iya haɗawa da bita na ɗan adam da canja wurin hannu idan an gano su, iri da yanke shawara sun kasance abin ganowa; cikakken aiki da kai shine aiwatarwa ɗaya maimakon ma'ana.
An tattara rata tsakanin wannan ma'anar da aiki. Abubuwan aikin gano peptide na AI-kore na yanzu sun kasance rarrabuwa kuma kawai suna da alaƙa da ra'ayin gwaji kawai., saboda tsinkaya, tsara, ingantawa da tabbatarwa akai-akai ana haɓaka su azaman yanki mai zaman kansa, don haka da kyar sakamakon gwaji ya sake yaduwa a cikin dukkan tsarin (Iyaka a Gano Drug, 2026). A 2026 Takardar da ta gabatar da kanta a matsayin bututun gano mai daidaitawa ta bayyana a sarari cewa ba ta ƙunshi ƙirar ƙira ba, babu ƙira na gwaji na tushen ilmantarwa kuma babu ra'ayi daga ingantaccen dakin gwaje-gwaje, musanya dabarun ba da amsa a maimakon haka; ya ba da fifiko 606 jerin daga tafkin kusan 16,000 'yan takara (Iyaka a Gano Drug, 2026).
Sakamakon aikace-aikacen yaƙin neman zaɓe shine cewa ƙirar-yin-gwaji-koyi peptide sake zagayowar yana da ƙarfi kawai kamar mafi ƙarancin ma'auninsa.. Ɗan takara ba ɗan takara ba ne har sai rikodin ya tsira daga haɗawa, tsarkakewa da tantancewa, kuma kowane ɓangaren da ke biyo baya ya ƙunshi wuri ɗaya da wannan rikodin ya ɓace.
Me yasa peptides da aka ƙera AI suka gaza a haɗuwa, da kuma yadda aka yi yuwuwar ƙima kafin matsayi?
Fitar da aka yi amfani da su a cikin bincike ɗaya zaɓin ƙira ne don ajin da aka yi niyya da hanyar haɗin kai. Hydrophobicity, Abubuwan da ke cikin cysteine da ragowar hydrophobic a jere yakamata a tantance su daidai da aikin da aka yi niyya; ƙayyadaddun yankewa na iya ware peptides masu amfani da membrane mai aiki ko disulfide.
Wannan tace tana wanzuwa saboda yanayin gazawar sananne ne ga mutanen da ke gudanar da sinadarai. Haka preprint bayanin kula cewa macrocycles na iya zama ƙalubale don haɗawa kuma aikin da ya gabata ya ba da rahoton babban gazawar ƙimar a matakin haɗin gwiwa., wanda shine dalilin da ya sa aka yi amfani da ƙarin ma'auni (Latent-X preprint, Latent Labs, 2025-07-22). Makin lissafin ba zai rufe wannan gibin ba. Makin samun damar roba madaidaici ne wanda ke ba da wata hanya ta roba, reagent samuwa, dauki yawan amfanin ƙasa, wahalar tsarkakewa, farashi, scalability ko sarrafa stereochemical, don haka ingantaccen makin damar samun damar roba ana hasashen iya aiki, ba hujjar kira ba (Ƙimar Ƙwayoyin Halitta na AI don Gano Magunguna, 2026-07).
Maki mai yiwuwa kuma dole ne ya kasance mai gaskiya game da ƙima. A cikin yaƙin neman zaɓe, 30 an ƙaddamar da ƙira ta kowane manufa da 77% (MCL-1), 57% (MDM2) kuma 87% (PD-L1) an yi nasarar haɗa su da yin keken keke a sama 90% tsarki (Latent-X preprint, Latent Labs, 2025-07-22). Waɗannan su ne sakamakon haɗin kai. An bayar da rahoton ƙimar dauri don wannan kamfen ɗin, 100.0% (MCL-1), 90.9% (MDM2) kuma 94.1% (PD-L1), an auna a kan 11 ku 17 zayyana kowane manufa da aka zaɓa don ƙima mai ɗaurewa, don haka kashi biyun suna zaune akan ma'auni daban-daban kuma bai kamata a taɓa ninka su tare azaman mazurari ɗaya ba (Latent-X preprint, Latent Labs, 2025-07-22).
Ta yaya solubility da tarawa ke yanke shawarar ko ɗan takara yana da amfani wajen tantancewa?
Solubility da aggregation yanke shawarar amfani saboda tara peptide yana haifar da sakamakon kima da ba za a iya fassara shi ba., kuma sakamakon da ba a iya fassarawa yawanci ana rubuta shi azaman mara kyau. Halayen mafi girman mahimmanci ga peptide pharmaceutical sune jerin farko, tsarin sakandare, oligomer da aggregation jihar, da ƙazanta da kayayyakin ƙazanta, wanda ke sanya tarawa tare da ainihin jerin sunayen maimakon ɗaukar shi azaman tsari bayan tunani (USP, Matsayin Magana don Taimakawa Ingantattun Magungunan Magungunan Peptide, 2023-03-22).
Amsar aiki shine ganowa maimakon tsinkaya. Gudanar da gwajin a cikin abin da aka yi niyya, duba farantin don turbidity kafin karanta siginar, da yin rikodin lura tare da sakamakon. A peptide wanda ya bayyana a fili 10 micromolar da turbid a 50 micromolar yana da iyakacin solubility, ba matsala mai ƙarfi ba, kuma su biyun suna buƙatar bibiya daban-daban.
Wanne kwanciyar hankali al'amurra, kuma yaushe ne gyaran sinadarai ke gyarawa?
Lamunin kwanciyar hankali yana da mahimmanci lokacin da suka rage rayuwar peptide a cikin gwajin ko a cikin plasma a ƙasan taga gwajin yana buƙata., kuma gyare-gyaren sinadarai shine gyara kawai lokacin da ƙayyadadden ƙirar binciken zai iya nuna haɓakawa. Mafi cikakken kwatancen jama'a ya fito ne daga jerin gwanon GLP-1 wanda aka auna akan proteinase K: GLP-1-nau'in daji yana da rabin rayuwa na proteolysis 9 mintuna, analogues guda ɗaya stapled sun kai 30 kuma 120 mintuna, kuma analog din dinki biyu ya kai 220 mintuna, fiye da ninki 24 tare da nau'in daji (Cromm et al., GLP-1 agonists na hydrocarbon, 2016). Irin wannan jerin a cikin ex vivo linzamin kwamfuta plasma ya ba da rabin rayuwa 14 mintuna don GLP-1, 320 mintuna don analog ɗin dinki da 170 minti don semaglutide, don haka an dinke GLP-1 analog ya tsira 24 sau da yawa fiye da peptide na asali a cikin gwajin proteolysis yayin da aka yarda da kwatancen ya sami haɓakar plasma mai ninki 12 ta hanyar daban. (Cromm et al., GLP-1 agonists na hydrocarbon, 2016).
Ina Q1A(R2) ƙirar kwanciyar hankali ya dogara da samfur, ajiya da ƙaddamarwa mahallin. Ga al'amarin gaba ɗaya, yanayi na dogon lokaci na iya zama 25 °C/60% RH ko 30 °C/65% RH; gwajin tsaka-tsaki yana da sharadi, ba ƙarin ƙarin watanni shida na duniya ba. Reagents na bincike suna buƙatar ingantaccen tsarin kwanciyar hankali na amfani maimakon ɗaukar fakitin bayanan rajista ta atomatik. Ina Q1A(R2).
Ta yaya tsarkakewa ta kofa madauki, kuma me ake nufi da danyen mai da tsarkin karshe?
AI-tsara peptide tsarkakewa kofofin da madauki domin tsarki ne da aka ayyana ma'auni tare da bayyana hanya, kuma danyen tsarki ba daidai yake da tsarkin karshe ba. Tsarkakewa ta hanyar ma'aunin taro, tare da kowane ƙazanta da za a iya ganowa an cire su 100%, ita ce hanyar pharmacopoeial: abubuwan da ke da alaƙa da peptide, sabani, ruwa, ragowar kaushi da sauran abubuwan da ba sa ƙonewa kowanne ana auna su, kuma lissafin ya raba ƙazantar chromatographic da aka ruwaito a matsayin kashi na jimlar yanki da aka gano daga juriya da sauran ƙazantattun da aka auna nauyi don nauyi. (USP, Matsayin Magana don Taimakawa Ingantattun Magungunan Magungunan Peptide, 2023-03-22). Wannan ma'anar ita ce hanya ta ƙimar ƙimar USP don ƙa'idodin tunani, ba ƙayyadaddun sakin gaba ɗaya ba, da kuma bambance-bambancen lokacin da takaddun shaida ya faɗi lamba ɗaya mai tsarki ba tare da faɗin hanyar da ta samar ba. An tsara iyakar ƙimar ingancin sifa na hukuma don abubuwan maganin peptide na roba an tsara su a cikin babin kantin magani kan halayen ingancin peptide na roba. (USP-NF Janar Babi <1503>).
A aikace, tsarkakewa ciniki ne tsakanin faɗin taga juzu'i da dawo da kayan. Ƙaƙƙarfan taga yana ɗaga tsarki na ƙarshe kuma yana watsar da ƙarin haɗin; wani faffadan taga yana dawo da ƙarin peptide kuma yana ɗaukar abubuwan haɓakawa a hankali, gami da isomers na matsayi wanda ya bambanta da manufa ta saura guda. Ba a sami tabbataccen adadi na farko na shirye-shiryen-HPLC na dawo da peptides masu wahala ba don wannan bita, don haka ya kamata a tattauna batun farfadowa tare da mai siyarwa azaman hanyar tambaya maimakon kwatanta da ma'auni da aka buga. Wannan taka tsantsan ya shafi ma'auni: tsafta fiye da kima na iya rage yawan amfanin ƙasa da haɓaka farashi a sikelin, wanda shine dalilin da ya sa aka fi bayyana manufa mai tsabta a matsayin dacewa-da-manufa, ko danyen abu ne ko abin da aka zubar, 70%, 85% ko 95%, maimakon saita a mafi girma da ake samu ta tsohuwa.
Waɗanne ma'aunin ƙididdiga ne ke dawowa cikin ƙirar, da kuma yadda aka ware halayen inganci guda biyar?
Ma'aunai waɗanda ke mayar da su cikin ƙirar su ne waɗanda ke gano kwayoyin halitta kuma su ƙididdige shi daban, saboda kashi ɗaya na tsafta ba zai iya ɗaukar bayanan jeri ba, yanayin tarawa da gurɓataccen gurɓataccen abu a lokaci ɗaya. Ma'anar FDA na peptide kamar 40 amino acid ko ƙasa da haka shine iyaka wanda ke ƙayyadaddun tsammanin tsari na aiki, kuma peptide Pharmaceuticals za a iya la'akari da iri ɗaya ko da kuwa an yi su da synthetically ko recombinantly., wanda shine dalilin da ya sa kunshin nazari, ba hanya ba, shine abin kwatankwacinsa (USP, Matsayin Magana don Taimakawa Ingantattun Magungunan Magungunan Peptide, 2023-03-22).
|
Sifa mai inganci |
Abin da yake aunawa |
Abin da bai gaya muku ba |
Filin rikodin da ke ɗauke da shi |
|---|---|---|---|
|
Tsafta |
Ma'auni na taro bayan cire duk ƙazantattun abubuwan da ake iya ganowa, tare da ƙazanta na chromatographic a matsayin kashi na jimlar yanki da aka gano |
Gano jerin jerin, jihar tari, ko babban kololuwa shine isomer da aka nufa |
Hanyar tsarki da sakamako, tare da tushen lissafin da aka bayyana |
|
Shaida |
Ko kayan ya dace da jerin da aka nufa |
Fmoc Protein Synthesis Matsayin tsarki ko kasancewar ƙazanta masu alaƙa |
Mass spectrometry and orthogonal ainihi sakamakon |
|
Yanar gizo na peptide |
Yawan Peptide a kowace naúrar abu, gyara Fmoc Solid Phase Synthesis don fuskantar, ruwa da sauran kaushi |
Ayyukan halitta ko bayanin ƙazanta |
An bayyana sakamakon binciken abun ciki tare da sigar ƙima |
|
Kwanciyar hankali Ghrelin Synthesis |
Canji a cikin abubuwan da ke sama ƙarƙashin ƙayyadaddun yanayin ajiya |
Masu kera Peptide Halayyar a tantance maida hankali ko a cikin plasma |
Yanayin ajiya, lokaci da kuma bayanai Trend |
|
Assay dacewa |
Ko kayan yana aiki a cikin tsarin gwajin da aka yi niyya |
Natsuwa na dogon lokaci ko haɓaka sikelin |
Binciken maida hankali, buffer da lura da solubility |
Shaida, tsabtar yanki, abun ciki, kwanciyar hankali da dacewa da ƙananan ƙwayoyin cuta tambayoyi daban-daban ne. Zabi endotoxin ko gwajin haifuwa inda aka gwada, tsari, hanya ko abubuwan da suka dace sun tabbatar da shi; tuntuɓar sel masu al'ada kaɗai baya sa gwajin haifuwar USP ya zama tilas.
Menene madaidaicin madauki yayi kama lokacin da yake gudana a zahiri, da abin da ya fara karya?
Zanga-zangar dakin gwaje-gwaje masu cin gashin kansu a cikin wasu azuzuwan kayan suna kwatanta dabarun tafiyar aiki, ba kayan aikin peptide ba. Yi ƙididdige madauki da aka tsara ta amfani da nasa kirar, tsarkakewa, halayyar da lokutan tantancewa, gami da gazawar gudanar da bita.
Ƙarƙashin waɗannan tsarin shine haɓakawa. Kayan aikin ƙira suna cikin mafi ƙarancin abubuwan haɗin kai na ɗakin binciken tuƙi, kuma matsalolin haɗin kai sau da yawa ba su da tabbas, tare da wasu al'amurra da rashin jituwa kawai ana iya gano su bayan an sami robots da hardware (Moran, Xu & Abolhasani, npj Robotics, 2026-05-16). Farashin kayan masarufi shine takura ta biyu: Peptide P Manufacturer kasuwanci kashe-da-shiryayye ruwa mai sarrafa mutummutumi matsakaita game da $40,000 kowace raka'a, wanda ke iyakance damar shiga, kuma ana kawo madaidaicin hanyar buɗe tushen mai rahusa a kusan $710 gaba daya (Moran, Xu & Abolhasani, npj Robotics, 2026-05-16). Ya kamata a karanta adadin saurin haɓaka da aka ruwaito tare da kulawa, saboda adadi 1000 da 350 sun fito ne daga a 2026 sake duba sake ba da rahoton kamfen na baya maimakon daga sabbin ma'auni (Moran, Xu & Abolhasani, npj Robotics, 2026-05-16).
Don aikin peptide, da "to menene" shine matakan yin da gwaji sune waɗanda za'a iya sarrafa su ta atomatik a yau, yayin da ƙirar ƙira da tantancewa shine ɓangaren da dole ne a gina shi da gangan. Yaƙin neman zaɓe wanda ke sarrafa haɗawa da tantancewa amma ya bar littafin canja wurin bayanai yana da farashin sarrafa kansa ba tare da ƙimar koyo ba..
Ta yaya mai karatu zai yi hukunci ga mai kaya kafin a fara aiki?
Ya kamata a yi wa mai siyarwa hukunci akan ƙayyadaddun bayanai da ya nema da takamaiman bayanan da ya dawo da su., ba akan lambar tsarkin kanun labarai ba. Abubuwan shigar da ke tantance ko jerin masu wahala sun yi nasara sune jerin a lambar harafi ɗaya tare da sauran abubuwan da ba daidai ba., saboda hadaddun motifs na iya buƙatar madadin sinadarai ko tsarin haɗin kai; da manufa taro, tun 10 g, 100 g kuma 1 kg canza guduro zabi, girman jirgin ruwa, tsarkakewa da jadawali; manufa mai dacewa da manufa; da gishiri ko counterion form, saboda TFA da acetate na iya rinjayar solubility, dacewa da hanyoyin ƙasa; gyare-gyare, daga ajali, lakabi, phosphorylation, hawan keke, PEG, lipid da linker suna canza ƙirar hanya, hadaddun tsarkakewa da nazari; da buƙatun QC da suka dace da aikace-aikacen.
Jerin abubuwan da aka riga aka tsara wanda ke biye daga shaidar da ke sama:
-
Tambayi ko an duba jeri a kan ruwa da kuma ka'idojin gudanar da ruwa da ruwa kafin fa'ida, da abin da mai kaya ke yi idan jerin sun gaza su.
-
Nemi hanyar tsarki da tushen lissafin sa, ba kawai kashi ɗaya ba, tun da taro-daidaita tsarki da chromatographic-yankin tsarki ne daban-daban yawa.
-
Nemi ƙayyadaddun ƙayyadaddun ƙayyadaddun taro da bayanan HPLC maimakon chromatogram na wakilci.. Peptides Suppliers
-
Tambayi yadda ake kula da haifuwa da endotoxin idan kayan zai tuntuɓi sel, kuma wane babi ne gwajin ya biyo baya.
-
Tambayi abin da zai faru da taga juzu'i a sikelin, kuma ko mafi girman darajar tsarki zai rage yawan amfanin ƙasa.
-
Tambayi wanda ke bitar hanyar lokacin da jerin ya ƙunshi disulphide-rich, Multi-phosphorylated ko aggregation-prone motifs.
Mai sayarwa wanda ke amsa waɗannan tambayoyin tare da sunaye na hanya da filayen rikodin yana bayanin tsari. Wanda ya ba da amsa tare da ƙimar tsarki kaɗai yana kwatanta kasida. Masu karatu waɗanda ke son yin aiki ta cikin jerin abubuwan da aka jera akan takamaiman jeri na iya magana da ƙwararrun fasaha kuma su nemi takamaiman bayanan nazari kafin a fara aikin..
Ina har yanzu madauki ya karye, da abin da zai canza?
Har ila yau madauki yana karye a lokacin da ake ɗaukar sakamakon lissafi a matsayin shaida mai ƙarfi fiye da yadda yake, kuma gyara shine kimantawar da aka tsara maimakon mafi kyawun maki guda. Binciken gwaji ya kasance da wuya: shirye-shiryen ƙirar ƙira da aka ambata da yawa ana ambaton su daidai saboda irin waɗannan rahotannin ba a saba gani ba, dukansu sun fito ne daga rukunin masana'antu guda ɗaya, kuma mafi yawan nazarin hanyoyin suna tsayawa ne a kimar lissafi (Ƙimar Ƙwayoyin Halitta na AI don Gano Magunguna, 2026-07). Inda bibiya ke faruwa, atrition a bayyane: na 54 ya haifar da peptides antimicrobial waɗanda aka haɗa su a zahiri, 21 ya kai bakin aiki na 50 micrograms da milliliter 10 kai 10 micrograms da milliliter da E. coli, tare da 9 gano a matsayin marasa guba da aiki (CVAE-BIO nazarin peptide antimicrobial, 2026). Wadancan kashi dari sun bayyana kima daya, daya pathogen da daya kofa, ba ƙimar nasara gabaɗaya don peptides da aka tsara AI ba.
Kwatancen ma'auni yana nuna yaduwa iri ɗaya. RFpeptides sun sami damar ganowa a cikin 38% na MDM2 kayayyaki da 21% Farashin MCL-1, kamar yadda aka ruwaito a cikin Latent-X kwatanta, a kan 90.9% kuma 100.0% buga rates da aka ruwaito don manufa iri ɗaya ta sabon samfurin, ko da yake yakin biyu sun yi amfani da ƙididdiga daban-daban da ƙididdiga (Latent-X preprint, Latent Labs, 2025-07-22). Tushen shaidar bai riga ya goyi bayan ingantaccen ƙiyasin sau nawa ƙira ke rayuwa daga tsara zuwa sakamako mai amfani ba, kuma hanyoyin da aka bita anan ba su rufe shirye-shirye na farfadowa ko haɓakawa a matsayin aikin tsayin jeri.
Abin da zai canza shi ne yarjejeniyar rahoto. Yaƙin neman zaɓe wanda ke buga cikakken mazugin kimantawa, ƙira nawa aka ƙirƙira, nawa ne suka wuce tacewa mai yiwuwa, nawa aka hada, nawa ne aka tsarkake zuwa ƙayyadaddun bayanai da nawa ne suka samar da bayanan tantancewa, yana ba ƙungiyar ta gaba wani abu don shiryawa. Har sai hakan ya zama misali, ka'idar yanke shawara ta tsaya: maki yiwuwa kafin daraja, gwada solubility kafin iko, kuma suna buƙatar takamaiman bayanan nazari kafin haɓakawa.
Tambayoyin da ake yawan yi
Abin da ke sanya peptide AI-tsara maimakon AI kawai?
An ƙera peptide AI lokacin da ƙirar ƙira ta ba da shawarar jerin da kanta, maimakon tsarin zura kwallaye da mutane suka rigaya suka rubuta. Bambance-bambancen yana da mahimmanci ga yuwuwar haɗakar peptide, saboda jerin da aka samar ba shi da tarihin gwaji na farko a bayansa. FDA ta zana layinta a 40 amino acid, kula da kwayoyin da ke ƙarƙashin wannan tsayin a matsayin peptide ko an yi shi ta hanyar synthetically ko recombinantly., da kuma la'akari da hanyoyi guda biyu don samar da abu ɗaya (Jagorar FDA akan samfuran magungunan peptide, 2024). Tsawon saboda haka iyakar tsari ne, ba lakabin zane ba.
Yawancin peptides da aka ƙera AI yawanci suna tsira zuwa ɗan takara da za a iya gwadawa?
Ƙarfafawa na al'ada ne kuma yana faruwa a bangarorin biyu na benci. Tace-mataki-mataki suna cire ƙira kafin kowace sinadari ta fara, da kuma 38.9% adadi daga gwaji guda ɗaya kuma ƙwayar cuta guda ɗaya tana nuna yadda ƙarin raguwa ke faruwa da zarar an auna aiki a ƙarƙashin kofa ɗaya. (CVAE-BIO nazarin peptide antimicrobial, 2026). Wannan lambar tana bayyana ayyukan kamfen ɗin guda ɗaya, ba adadin tsira ga peptides da aka ƙera gabaɗaya ba, kuma babu wata majiya da aka yi nazari a nan ta bayar da rahoton wani adadi na yakin neman zabe.
Ya kamata a yi jerin abubuwa ta hanyar sinadarai ko recombinantly?
Haɗin sunadarai yana ɗaukar mafi yawan ƙananan magungunan peptide, da tsaga tsayin waƙoƙi, nauyin kwayoyin halitta da rikitarwar tsari maimakon fifiko. Wani bincike na ƙananan magungunan peptide da aka amince da su kwanan nan ya gano cewa yawancin an haɗa su ta hanyar sinadarai (MOL Yana Canja takaddar fasaha akan zaɓin hanya, 2025). Sake magana ya zama hanya mai amfani yayin da sarƙoƙi ke tsawaita kuma buƙatun nadawa suka bayyana, wanda shine dalilin da ya sa layin ka'idoji 40-rago da kuma layin masana'anta sukan zauna a wurare daban-daban.
Abin da ke tafiyar da tsarin lokaci daga ƙira zuwa bayanan farko na tantancewa?
Matakin dauri ba kasafai yake takurawa ba; kira, tsarkakewa da jerin gwano suna. Ƙididdigar ƙima da nasarar hawan keke da aka bayar da rahoton don maƙasudin macrocycle sun nuna nawa jadawalin wani ƙaƙƙarfan ƙaƙƙarfan ƙaya zai iya ɗauka kafin auna guda ɗaya. (Latent-X preprint, Latent Labs, 2025-07-22). Takamaiman farashin Peptide da ƙididdiga na tsawon lokaci sun dogara ne akan jeri, sikelin da tsarkin manufa, kuma majiyoyin da aka bita a nan ba su kawo su ba.
Shin madaidaicin madaidaicin ma'anar yana nufin ana iya yin peptide?
A'a. Maki mai kyau shine siginar matsayi, ba hujjar kira ba, wanda shine dalilin da ya sa madaidaicin madaidaicin ƙima ba hujja ba ce ta haɗawa kuma bai kamata a taɓa ɗaukar shi azaman koren haske da kanta ba. (Ƙimar Ƙwayoyin Halitta na AI don Gano Magunguna, 2026-07). Makin yana taƙaita kaddarorin da aka annabta; ba ta da hanya, yawan amfanin ƙasa ko bayanan stereochemical.
Me ya kamata ku yi lokacin da dan takara ya kasa a tsarkakewa maimakon a kira?
Bi da shi azaman shigarwar madauki, ba matattu ba. Rashin tsaftar peptide da aka ƙera ta AI yawanci yana zuwa ga ƙazanta masu alaƙa, tarawa ko tarkacen da ba zai rabu da tsafta ba, da rikodin jerin tare da chromatogram sun gaya muku wanne. Ciyar da duka biyu a cikin zagaye na gaba na ƙira, tun da zagayowar ƙira-yi-gwaji-koyi peptide sake zagayowar da ke watsar da bayanan tsarkakewa yana koyo ne kawai daga rabin sakamakonsa..
Kammalawa
Aiwatar da lissafin bincike zuwa jeri ɗaya: yiwuwa, ainihi, hanyar tsarki, tushen abun ciki, farfadowa, kwanciyar hankali da kula da ƙananan ƙwayoyin cuta masu dacewa. Yarda da yadda za'a tantance sauye-sauye da ma'auni, da kuma danganta sakamakon da aka auna baya zuwa rikodin ƙira.
